ecDNA and Immune Modulation

Cancer involves gene amplification, which occurs either through chromosome expansion or formation of circular extrachromosomal DNA (ecDNA). The development and progression of cancer rely heavily on ecDNA. The independent cellular structure of ecDNA contains oncogenes, which drive tumor progression and treatment resistance. Studies have demonstrated how ecDNA modifies the tumor environment by controlling immune system responses. The presence of ecDNA in cancer cells enables them to evade immune surveillance through modifications in antigen presentation and by establishing an immunosuppressive network, which reduces the effectiveness of CAR-T cell therapy and immune checkpoint inhibitors. The approach of targeting ecDNA demonstrates great promise for cancer immunotherapy, yet multiple obstacles remain. The varied nature of ecDNA across tumor samples creates difficulties in creating standardized therapeutic approaches. The fluid dynamics of ecDNA allow cancer cells to transform rapidly, which makes current medical interventions ineffective. The development of CRISPR-based gene editing and genome sequencing improvements may solve problems caused by ecDNA in cancer. Further research is required to understand immune modulation effects of ecDNA for creating effective treatments. Research into the combination of ecDNA targeting methods with current immunotherapies should be the main focus of future studies to enhance treatment outcomes for patients. The resolution of these obstacles has the potential to transform cancer treatment methods while creating individualized therapeutic approaches.